Eckert & Ziegler Expands Actinium-225 Production to Support Growing Demand for Targeted Cancer Therapies

Eckert & Ziegler Expands Actinium-225 Production to Support Growing Demand for Targeted Cancer Therapies

(IN BRIEF) Eckert & Ziegler and the Nuclear Physics Institute of the Czech Academy of Sciences have scaled up production of the critical medical isotope Actinium-225, moving from development into larger-scale manufacturing at facilities in Řež and Braunschweig. The expansion enables the delivery of clinically meaningful quantities of the isotope, which is increasingly used in targeted radiopharmaceutical therapies for cancer but has faced supply limitations due to production complexity. By increasing manufacturing capacity and strengthening global availability, the collaboration supports the advancement of precision oncology and the development of next-generation diagnostic and therapeutic solutions.

(PRESS RELEASE) BERLIN/ ŘEΖ, 17-Feb-2026 — /EuropaWire/ — Eckert & Ziegler SE and the Nuclear Physics Institute of the Czech Academy of Sciences (ÚJF) have advanced their joint Actinium-225 programme into scaled manufacturing, utilising production facilities in Řež, Czech Republic, and Braunschweig, Germany. The transition marks a significant step toward addressing the limited global availability of this highly sought-after medical radioisotope.

With increased output per production run, Eckert & Ziegler now ranks among the small group of suppliers capable of delivering clinically relevant quantities of Actinium-225. The isotope is considered one of the most promising alpha emitters for targeted radiopharmaceutical therapies, particularly for treating small tumours and micrometastases, yet its broader adoption has historically been restricted by complex production requirements and constrained supply.

The move to continuous, higher-capacity manufacturing is intended to strengthen supply security for pharmaceutical developers and research institutions working on next-generation cancer diagnostics and treatments. By expanding radionuclide production capabilities, the partners aim to support the accelerating demand for precision oncology applications based on targeted radiotherapy.

Eckert & Ziegler already provides several key medical isotopes—including Gallium-68, Lutetium-177 and Yttrium-90—to healthcare and research organisations worldwide. Combined with its expertise in isotope production, global distribution and contract development and manufacturing services, the company continues to position itself as a key enabler of innovation in the radiopharmaceutical sector.

Headquartered in Germany and listed on the TecDAX index, Eckert & Ziegler employs more than 1,000 people and offers products and services spanning early-stage research through to commercial manufacturing and distribution for nuclear medicine and radiation therapy.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.

Contributing to saving lives.

Media Contact:

Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

SOURCE: Eckert & Ziegler SE